Brokerages up price targets on rising Sun, some point to clouds
Synopsis
Motilal Oswal has raised target price to Rs 900 and maintained a ‘buy’ rating on the back of improving traction in specialty products. Edelweiss has upgraded the stock to ‘buy’ and raised target price to Rs 950 from Rs 675. CLSA has raised target price to Rs 960 from Rs 850 and maintained a ‘buy’ rating.
Mumbai: Brokerages have raised target price on Sun Pharmaceutical Industries after the drug major on Friday reported June quarter earnings that exceeded market expectations.
Motilal Oswal has raised target price to Rs 900 and maintained a ‘buy’ rating on the back of improving traction in specialty products. Edelweiss has upgraded the stock to ‘buy’ and raised target price to Rs 950 from Rs 675. CLSA has raised target price to Rs 960 from Rs 850
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
Already a Member? Sign In now
Get Offer
Why ?
-
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
-
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.